Omeros Corp (OMER)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

201 ELLIOTT AVENUE WEST SEATTLE, WA 98119

Omeros Corporation, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing products on inflammation and disorders of the central nervous system. Its product candidates are derived from its proprietary PharmacoSurgery platform, which is designed to improve the clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological, and other surgical and medical procedures. The company's lead PharmacoSurgery product candidate, OMS103HP, is in two Phase 3 clinical programs to improve postoperative joint function and reduce pain following arthroscopic anterior cruciate ligament reconstruction surgery, and to reduce pain and improve postoperative joint function following arthroscopic meniscectomy surgery. Its product candidates also include OMS302 for use during ophthalmological procedures, including cataract and other lens replacement surgery; and OMS201 for use during urological surgery, including uroendoscopic procedures of the bladder, ureter, urethra, and other urinary tract structures. The company's pre-clinical developmental programs comprise MASP-2 program, in which it is developing antibody therapies to treat disorders caused by complement activated inflammation; cartilage protective program to treat cartilage disorders, such as osteoarthritis and rheumatoid arthritis; and Phosphodiesterase 10 program for the treatment of schizophrenia; GPCR program to treat a series of CNS disorders. Omeros Corporation was founded in 1994 and is based in Seattle, Washington.

Data as of 2021-04-17 10:17:56 -0400
Market Cap1.138 Billion Shares Outstanding61.934 Million Avg 30-day Volume550.571 Thousand
P/E Ratio-8.24073 Dividend Yield0.0 EPS-2.41
Price/Sales15.3 Debt to Equity-1.5 EBITDA-108.985 Million
Price to Book Value-9.35 Forward PE-10.27 Enterprise Value1.232 Billion
Total Cash134.953 Million Current Debt36.736 Million Gross Profit72.911 Million
BETA0.0 52-week High/Low23.85 / 9.25 Next Earnings Date2021-05-10 Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from OMER instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 1 1 0.0% 1 (0.06%) 1 (0.06%) 0.0%
Funds Holding: 136 138 -1.45% 35 (2.1%) 38 (2.37%) -7.89%
13F shares: 34.213 Million 34.906 Million -1.99% 16.031 Million 16.99 Million -5.65%
% Ownership 55.4926 56.6174 -1.99% 26.0018 27.5574 -5.64%
New Positions: 16 31 -48.39% 6 17 -64.71%
Increased Positions 43 59 -27.12% 7 13 -46.15%
Closed Positions 17 16 6.25% 9 8 12.5%
Reduced Positions 42 24 75.0% 17 5 240.0%
Total Calls 2.41 Million 2.125 Million 13.45% 1.191 Million 1.287 Million -7.47%
Total Puts 841.55 Thousand 703.423 Thousand 19.64% 81.4 Thousand 255.8 Thousand -68.18%
PUT/CALL Ratio 0.35 0.33 6.06% 0.07 0.2 -65.0%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding OMER (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding OMER BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

90.7 Thousand total shares from 4 transactions

Exercise Derivative Conversion (M)

100.7 Thousand total shares from 6 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

DEMOPULOS GREGORY A MD CHAIRMAN, CEO & PRESIDENT

4,384,030 2021-04-07 1

DEMOPULOS PETER A MD

198,516 2021-02-22 2

JACOBSEN MICHAEL A VP FINANCE AND CAO

166,100 2021-02-19 3

HOOD LEROY E. MD PHD

74,390 2021-02-12 2

CABLE THOMAS J.

35,067 2021-01-13 3

CANCELMO PETER B VP, GEN. COUNSEL & CORP. SEC.

0 2020-10-26 1

ASPIRI RAY

0 2020-06-05 1

HANISH ARNOLD C

0 2020-06-05 1

SHAH RAJIV

0 2020-06-05 1

BUMOL THOMAS F.

0 2020-06-05 1

ZUMWALT KURT

  • Director
1,000 2020-02-10 0

KELBON MARCIA S. VP PATENT AND GENERAL COUNSEL

  • Officer
210,645 2019-06-07 0

SPIEGELMAN DANIEL K

  • Director
0 2012-06-01 0

TRIPET JEAN-PHILIPPE

  • Director
0 2011-05-27 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

DEMOPULOS GREGORY A MD CHAIRMAN, CEO & PRESIDENT

2021-04-08 19:52:18 -0400 2021-04-08 S 35,206 $17.76 d 2,026,986 direct yes -7.1311 0.768 0.9874 5 -7.1311 2

DEMOPULOS GREGORY A MD CHAIRMAN, CEO & PRESIDENT

2021-04-08 19:52:18 -0400 2021-04-08 M 35,206 d 147,426 direct

DEMOPULOS GREGORY A MD CHAIRMAN, CEO & PRESIDENT

2021-04-08 19:52:18 -0400 2021-04-08 M 35,206 $4.10 a 2,062,192 direct -7.1311 0.768 0.9874 5 -7.1311 2

DEMOPULOS GREGORY A MD CHAIRMAN, CEO & PRESIDENT

2021-04-08 19:52:18 -0400 2021-04-07 M 37,407 d 182,632 direct

DEMOPULOS GREGORY A MD CHAIRMAN, CEO & PRESIDENT

2021-04-08 19:52:18 -0400 2021-04-07 S 37,407 $17.91 d 2,026,986 direct yes -7.1311 0.768 0.9874 5 -7.1311 2

DEMOPULOS GREGORY A MD CHAIRMAN, CEO & PRESIDENT

2021-04-08 19:52:18 -0400 2021-04-07 M 37,407 $4.10 a 2,064,393 direct -7.1311 0.768 0.9874 5 -7.1311 2

DEMOPULOS PETER A MD

2021-02-23 18:43:42 -0500 2021-02-22 M 5,000 d 0 direct

JACOBSEN MICHAEL A VP FINANCE AND CAO

2021-02-23 17:20:37 -0500 2021-02-22 M 8,100 d 65,000 direct

JACOBSEN MICHAEL A VP FINANCE AND CAO

2021-02-23 17:20:37 -0500 2021-02-22 M 8,100 $10.27 a 22,100 direct -14.4509 -11.2939 -21.2539 0.0 1 -21.2539 31

DEMOPULOS PETER A MD

2021-02-23 18:43:42 -0500 2021-02-22 M 5,000 $4.53 a 198,516 direct -14.4509 -11.2939 -21.2539 0.0 1 -21.2539 31

DEMOPULOS PETER A MD

2021-02-23 18:43:42 -0500 2021-02-22 M 5,000 d 0 direct

DEMOPULOS PETER A MD

2021-02-23 18:43:42 -0500 2021-02-22 M 5,000 $5.30 a 193,516 direct -14.4509 -11.2939 -21.2539 0.0 1 -21.2539 31

JACOBSEN MICHAEL A VP FINANCE AND CAO

2021-02-23 17:20:37 -0500 2021-02-22 S 8,100 $23.28 d 14,000 direct yes -14.4509 -11.2939 -21.2539 0.0 1 -21.2539 31

JACOBSEN MICHAEL A VP FINANCE AND CAO

2021-02-23 17:20:37 -0500 2021-02-19 M 10,000 $10.27 a 24,000 direct -14.4509 -11.2939 -21.2539 0.0 1 -21.2539 31

JACOBSEN MICHAEL A VP FINANCE AND CAO

2021-02-23 17:20:37 -0500 2021-02-19 M 10,000 d 73,100 direct

JACOBSEN MICHAEL A VP FINANCE AND CAO

2021-02-23 17:20:37 -0500 2021-02-19 S 10,000 $22.64 d 14,000 direct yes -14.4509 -11.2939 -21.2539 0.0 1 -21.2539 31

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
OMEROS CORP OMER 2021-04-16 22:15:03 UTC -0.6385 0.6985 200000
OMEROS CORP OMER 2021-04-16 21:45:03 UTC -0.6197 0.6797 200000
OMEROS CORP OMER 2021-04-16 21:15:02 UTC -0.6197 0.6797 200000
OMEROS CORP OMER 2021-04-16 20:45:03 UTC -0.6222 0.6822 200000
OMEROS CORP OMER 2021-04-16 20:15:04 UTC -0.6222 0.6822 200000
OMEROS CORP OMER 2021-04-16 19:45:03 UTC -0.6106 0.6706 200000
OMEROS CORP OMER 2021-04-16 19:15:03 UTC -0.6106 0.6706 200000
OMEROS CORP OMER 2021-04-16 18:45:03 UTC -0.5719 0.6319 200000
OMEROS CORP OMER 2021-04-16 18:15:03 UTC -0.5719 0.6319 250000
OMEROS CORP OMER 2021-04-16 17:45:03 UTC -0.5719 0.6319 250000
OMEROS CORP OMER 2021-04-16 17:15:03 UTC -0.5719 0.6319 250000
OMEROS CORP OMER 2021-04-16 16:45:02 UTC -0.5723 0.6323 250000
OMEROS CORP OMER 2021-04-16 16:15:03 UTC -0.5723 0.6323 250000
OMEROS CORP OMER 2021-04-16 15:45:03 UTC -0.5723 0.6323 250000
OMEROS CORP OMER 2021-04-16 15:15:03 UTC -0.5723 0.6323 250000
OMEROS CORP OMER 2021-04-16 14:45:03 UTC -0.6432 0.7032 250000
OMEROS CORP OMER 2021-04-16 14:15:02 UTC -0.6432 0.7032 250000
OMEROS CORP OMER 2021-04-16 13:45:03 UTC -0.6432 0.7032 250000
OMEROS CORP OMER 2021-04-16 13:15:03 UTC -0.6432 0.7032 250000
OMEROS CORP OMER 2021-04-16 12:45:02 UTC -0.6432 0.7032 200000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Advanced Series Trust- AST Academic Strategies Asset Allocation Portfolio OMER -7800.0 shares, $-111423.0 2020-12-31 N-PORT
AQR Funds- AQR Diversified Arbitrage Fund OMER -169689.0 shares, $-2424007.37 2020-12-31 N-PORT
Franklin Alternative Strategies Funds- Franklin K2 Alternative Strategies Fund OMER -19570.0 shares, $-226816.3 2020-11-30 N-PORT
THE LAZARD FUNDS, INC.- Lazard Enhanced Opportunities Portfolio OMER -5874.0 shares, $-83910.09 2020-12-31 N-PORT
JNL Series Trust- JNL Multi-Manager Alternative Fund OMER -41666.0 shares, $-595198.81 2020-12-31 N-PORT
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund OMER -600.0 shares, $-8571.0 2020-12-31 N-PORT

Elevate your investments